Schedule 13G ownership disclosure
NEWAMSTERDAM PHARMA COMPANY
Ordinary Shares, nominal value EUR0.12 per share · CUSIP: N62509109
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LP
Shares: 6,978,534 · Class: 6.5%
- Viking Global Opportunities Parent GP LLC
Shares: 6,978,534 · Class: 6.5%
- Viking Global Opportunities GP LLC
Shares: 4,675,619 · Class: 4.4%
- Viking Global Opportunities Portfolio GP LLC
Shares: 4,675,619 · Class: 4.4%
- Viking Global Opportunities Illiquid Investments Sub-Master LP
Shares: 4,675,619 · Class: 4.4%
- Viking Global Opportunities Drawdown GP LLC
Shares: 2,302,915 · Class: 2.2%
- Viking Global Opportunities Drawdown Portfolio GP LLC
Shares: 2,302,915 · Class: 2.2%
- Viking Global Opportunities Drawdown (Aggregator) LP
Shares: 2,302,915 · Class: 2.2%
- HALVORSEN OLE ANDREAS
Shares: 6,978,534 · Class: 6.5%
- Ott David C.
Shares: 6,978,534 · Class: 6.5%
- Shabet Rose Sharon
Shares: 6,978,534 · Class: 6.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-000679
- Form type
- SCHEDULE 13G/A
- Filer
- NewAmsterdam Pharma Co N.V.
- CIK
- CIK 1936258
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership